Kura, Kyowa say Phase 1 update supports menin inhibitor combos

Nicole DeFeudis

Editor

As Kura Oncology and Kyowa Kirin await an FDA decision for their oral menin inhibitor in acute myeloid leukemia, the partners are highlighting another early …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Kura, Kyowa say Phase 1 update supports menin inhibitor combos

Nicole DeFeudis

Editor

Sign up to read this article for free.

KalVista says FDA delayed decision on HAE drug, citing ‘heavy workload’

Another round of consolidation is coming, FDA commissioner tells staff

Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button'

AstraZeneca inks AI drug R&D deal with Chinese pharma for $110M upfront

FDA's oncology adcomm to review GSK's Blenrep relaunch plans

McKesson leads the charge in revolutionizing precision oncology in community practices

Ku­ra, Ky­owa say Phase 1 up­date sup­ports menin in­hibitor com­bos

Nicole DeFeudis

Editor

Sign up to read this article for free.

KalVista says FDA de­layed de­ci­sion on HAE drug, cit­ing ‘heavy work­load’

An­oth­er round of con­sol­i­da­tion is com­ing, FDA com­mis­sion­er tells staff

Bris­tol My­ers gets a key strate­gist with 'Team Shib­s'; Idor­sia to change CEOs af­ter it 'hit a re­set but­ton'

As­traZeneca inks AI drug R&D deal with Chi­nese phar­ma for $110M up­front

FDA's on­col­o­gy ad­comm to re­view GSK's Blenrep re­launch plans

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

Kura, Kyowa say Phase 1 update supports menin inhibitor combos

KalVista says FDA delayed decision on HAE drug, citing ‘heavy workload’

Another round of consolidation is coming, FDA commissioner tells staff

Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button'

AstraZeneca inks AI drug R&D deal with Chinese pharma for $110M upfront

FDA's oncology adcomm to review GSK's Blenrep relaunch plans

McKesson leads the charge in revolutionizing precision oncology in community practices